Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ScTIL210 in Malignant Solid Tumors
NCT04571892Phase 2Unknown
- Sponsor
- Shanghai East Hospital
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ScTIL in malignant solid tumor, sponsored by Shanghai East Hospital. Primary endpoint: The safety of ScTIL210 at 24 weeks. Status: unknown.
02
Drugs
ScTIL
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT04571892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571892.